

The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.
- All
- Blog
- Congress
- Scientific resource
- Webinar
- Poster
- Scientific publication
- Press release
- Press coverage
- News

The General Meeting of Oncodesign authorises the allocation of OPM
Each Oncodesign shareholder will receive one OPM share for one ONCODESIGN share held

Euronext Paris authorises the listing of OPM shares
Oncodesign Precision Medicine (OPM) and Oncodesign announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access + market in Paris of OPM’s ordinary shares.

Servier exercises the exclusive worldwide license option of their collaboration program LRRK2
Servier and Oncodesign Precision Medicine (OPM) announce that Servier has exercised its exclusive license option for their drug candidate

OPM and Servier announce a strategic collaboration to discover new therapeutic targets for pancreatic cancer treatment
Global pharmaceutical group Servier and Oncodesign Precision Medicine (OPM) announce a collaborative research agreement

Lewis acid catalyzed chemoselective and regioselective epoxide ring opening with sulfoximines
We report Sulfoximines with the first regioselective Epoxide Ring opening; these findings broaden their Drug Discovery and design applications. Read more.

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor Antagonist 177Lu-Satoreotide Tetraxetan and the Agonist 177Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours
Read now our new scientific publication focused on Anti-Tumour Activity!

ONCODESIGN announces the separation of its two business lines – Service and Biotech
ONCODESIGN today announced that the Board of Directors has approved the subsidiarisation of its Biotech business.

In vitro pharmacological profile of Compound A
Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease.

In vivo PK/PD profile of Compound A
Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor.

Parkinson’s Disease: Growing Prevalence And Continued Significant Medical Need
Explore the disease & find out about our strategic R&D collaboration with Servier: info, press releases & video!

Mouse models of hepatocellular carcinoma
Get to know more about our comprehensive & functional preclinical platform for immunotherapy research using mouse models (PDX, human transgenic mouse).

Using individual or a consortium of bacteria for immuno-oncology research
Get to know more about the beneficial role of bacteria for cancer therapy. Oncodesign Services, vector Of Innovation in oncology, inflammation & Covid-19.